Immunochina Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
IPO Registration
- Employees
-
266
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
30
Immunochina Pharmaceuticals General Information
Description
Developer of cell and gene therapies designed to treat malignant hematological diseases, solid tumors, and autoimmune disorders. The company utilizes proprietary technology platforms to develop autologous and allogeneic CAR-T drug candidates, enabling healthcare providers to offer advanced treatment options for conditions such as refractory non-Hodgkin lymphoma, colorectal cancer, and systemic lupus erythematosus.
Contact Information
Website
www.imunopharm.comCorporate Office
- Room 101, 1st Floor, Building 54
- No. 2 Yuquan Road, Haidian District
- Beijing, 100089
- China
Corporate Office
- Room 101, 1st Floor, Building 54
- No. 2 Yuquan Road, Haidian District
- Beijing, 100089
- China
Immunochina Pharmaceuticals Timeline
Immunochina Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. IPO | 30-Jun-2026 | Announced | Generating Revenue | |||
| 13. Secondary Transaction - Private | 01-Feb-2026 | Completed | Generating Revenue | |||
| 12. Secondary Transaction - Private | 01-Mar-2025 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series E) | 09-Jan-2025 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Private | 01-Jul-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series D1) | 01-Nov-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series D) | 24-Nov-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C2) | 22-Dec-2020 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C1) | 25-Sep-2020 | $14.6M | $45.1M | Completed | Generating Revenue | |
| 5. Later Stage VC (Series C) | 22-Jan-2019 | $20.5M | $30.4M | Completed | Generating Revenue |
Immunochina Pharmaceuticals Patents
Immunochina Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022143870-A1 | Antibody that specifically binds to bcma and application thereof | Inactive | 31-Dec-2020 | ||
| EP-4265638-A1 | Chimeric antigen receptor targeting cd123 and use thereof | Pending | 16-Dec-2020 | ||
| EP-4265638-A4 | Chimeric antigen receptor targeting cd123 and use thereof | Pending | 16-Dec-2020 | ||
| WO-2022127401-A1 | Chimeric antigen receptor targeting cd123 and use thereof | Inactive | 16-Dec-2020 | ||
| WO-2022121899-A1 | Antibody specifically binding to strep-tag ii tag and use thereof | Inactive | 08-Dec-2020 | C07K16/1292 |
Immunochina Pharmaceuticals Signals
Immunochina Pharmaceuticals Investors (30)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Beijing Haiguorongzhi Private Equity Fund Management | Corporate Venture Capital | Minority | ||
| Hosencare Brothers | Growth/Expansion | Minority | ||
| China Development Bank Capital | Fund of Funds | Minority | ||
| State Development and Investment Group | Government | Minority | ||
| SUNNOVO | Corporation | Minority |
Immunochina Pharmaceuticals FAQs
-
When was Immunochina Pharmaceuticals founded?
Immunochina Pharmaceuticals was founded in 2015.
-
Where is Immunochina Pharmaceuticals headquartered?
Immunochina Pharmaceuticals is headquartered in Beijing, China.
-
What is the size of Immunochina Pharmaceuticals?
Immunochina Pharmaceuticals has 266 total employees.
-
What industry is Immunochina Pharmaceuticals in?
Immunochina Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Immunochina Pharmaceuticals a private or public company?
Immunochina Pharmaceuticals is a Private company.
-
What is Immunochina Pharmaceuticals’s current revenue?
The current revenue for Immunochina Pharmaceuticals is .
-
How much funding has Immunochina Pharmaceuticals raised over time?
Immunochina Pharmaceuticals has raised $99M.
-
Who are Immunochina Pharmaceuticals’s investors?
Beijing Haiguorongzhi Private Equity Fund Management, Hosencare Brothers, China Development Bank Capital, State Development and Investment Group, and SUNNOVO are 5 of 30 investors who have invested in Immunochina Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process